192 related articles for article (PubMed ID: 37607227)
1. IL-15 synergizes with CD40 agonist antibodies to induce durable immunity against bladder cancer.
Wong JL; Smith P; Angulo-Lozano J; Ranti D; Bochner BH; Sfakianos JP; Horowitz A; Ravetch JV; Knorr DA
Proc Natl Acad Sci U S A; 2023 Aug; 120(35):e2306782120. PubMed ID: 37607227
[TBL] [Abstract][Full Text] [Related]
2. IL-15 synergizes with CD40 agonist antibodies to induce durable immunity against bladder cancer.
Wong JL; Smith P; Angulo-Lozano J; Ranti D; Bochner BH; Sfakianos JP; Horowitz A; Ravetch JV; Knorr DA
bioRxiv; 2023 Feb; ():. PubMed ID: 36778311
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cell targeting with Fc-enhanced CD40 antibody agonists induces durable antitumor immunity in humanized mouse models of bladder cancer.
Garris CS; Wong JL; Ravetch JV; Knorr DA
Sci Transl Med; 2021 May; 13(594):. PubMed ID: 34011627
[TBL] [Abstract][Full Text] [Related]
4. Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity.
Knorr DA; Dahan R; Ravetch JV
Proc Natl Acad Sci U S A; 2018 Oct; 115(43):11048-11053. PubMed ID: 30297432
[TBL] [Abstract][Full Text] [Related]
5. Augmented IL-15Rα expression by CD40 activation is critical in synergistic CD8 T cell-mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2 tumors in mice.
Zhang M; Ju W; Yao Z; Yu P; Wei BR; Simpson RM; Waitz R; Fassò M; Allison JP; Waldmann TA
J Immunol; 2012 Jun; 188(12):6156-64. PubMed ID: 22593619
[TBL] [Abstract][Full Text] [Related]
6. The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunity.
Mangsbo SM; Broos S; Fletcher E; Veitonmäki N; Furebring C; Dahlén E; Norlén P; Lindstedt M; Tötterman TH; Ellmark P
Clin Cancer Res; 2015 Mar; 21(5):1115-26. PubMed ID: 25316820
[TBL] [Abstract][Full Text] [Related]
7. Next Generation CD40 Agonistic Antibodies for Cancer Immunotherapy.
Salomon R; Dahan R
Front Immunol; 2022; 13():940674. PubMed ID: 35911742
[TBL] [Abstract][Full Text] [Related]
8. Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer.
Richman LP; Vonderheide RH
Cancer Immunol Res; 2014 Jan; 2(1):19-26. PubMed ID: 24416732
[TBL] [Abstract][Full Text] [Related]
9. Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer.
Sandin LC; Orlova A; Gustafsson E; Ellmark P; Tolmachev V; Tötterman TH; Mangsbo SM
Cancer Immunol Res; 2014 Jan; 2(1):80-90. PubMed ID: 24778163
[TBL] [Abstract][Full Text] [Related]
10. APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application.
Filbert EL; Björck PK; Srivastava MK; Bahjat FR; Yang X
Cancer Immunol Immunother; 2021 Jul; 70(7):1853-1865. PubMed ID: 33392713
[TBL] [Abstract][Full Text] [Related]
11. IL-15R alpha-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action through NK and CD8+ T cells proliferation and activation.
Wu Z; Xu Y
J Mol Cell Biol; 2010 Aug; 2(4):217-22. PubMed ID: 20671116
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer.
Zhang M; Yao Z; Dubois S; Ju W; Müller JR; Waldmann TA
Proc Natl Acad Sci U S A; 2009 May; 106(18):7513-8. PubMed ID: 19383782
[TBL] [Abstract][Full Text] [Related]
13. CD40 Agonist Restores the Antitumor Efficacy of Anti-PD1 Therapy in Muscle-Invasive Bladder Cancer in an IFN I/II-Mediated Manner.
Leblond MM; Tillé L; Nassiri S; Gilfillan CB; Imbratta C; Schmittnaegel M; Ries CH; Speiser DE; Verdeil G
Cancer Immunol Res; 2020 Sep; 8(9):1180-1192. PubMed ID: 32661095
[TBL] [Abstract][Full Text] [Related]
14. Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation.
Carpenter EL; Mick R; Rüter J; Vonderheide RH
J Transl Med; 2009 Nov; 7():93. PubMed ID: 19906293
[TBL] [Abstract][Full Text] [Related]
15. Synergistic augmentation of CD40-mediated activation of antigen-presenting cells by amphiphilic poly(γ-glutamic acid) nanoparticles.
Broos S; Sandin LC; Apel J; Tötterman TH; Akagi T; Akashi M; Borrebaeck CA; Ellmark P; Lindstedt M
Biomaterials; 2012 Sep; 33(26):6230-9. PubMed ID: 22687756
[TBL] [Abstract][Full Text] [Related]
16. Agonistic CD40 antibodies and cancer therapy.
Vonderheide RH; Glennie MJ
Clin Cancer Res; 2013 Mar; 19(5):1035-43. PubMed ID: 23460534
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD40 Antibody Fused to CD40 Ligand Is a Superagonist Platform for Adjuvant Intrinsic DC-Targeting Vaccines.
Ceglia V; Zurawski S; Montes M; Kroll M; Bouteau A; Wang Z; Ellis J; Igyártó BZ; Lévy Y; Zurawski G
Front Immunol; 2021; 12():786144. PubMed ID: 35095862
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies.
Li F; Ravetch JV
Science; 2011 Aug; 333(6045):1030-4. PubMed ID: 21852502
[TBL] [Abstract][Full Text] [Related]
19. CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation.
Reyes RM; Deng Y; Zhang D; Ji N; Mukherjee N; Wheeler K; Gupta HB; Padron AS; Kancharla A; Zhang C; Garcia M; Kornepati AVR; Boyman O; Conejo-Garcia JR; Svatek RS; Curiel TJ
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33849925
[TBL] [Abstract][Full Text] [Related]
20. Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting.
Salomon R; Rotem H; Katzenelenbogen Y; Weiner A; Cohen Saban N; Feferman T; Amit I; Dahan R
Nat Cancer; 2022 Mar; 3(3):287-302. PubMed ID: 35190724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
